Potential limitation of CCR5 antagonists: drug resistance more often linked to CXCR4-utilizing than to CCR5-utilizing HIV-1

AIDS. 2008 Nov 12;22(17):2393-5. doi: 10.1097/QAD.0b013e328312c72c.

Abstract

CCR5 antagonists are approved for treatment-experienced individuals, who are at risk of harboring both drug-resistant and CXCR4-utilizing (X4) HIV-1. If CXCR4 usage and drug resistance are linked, CCR5 antagonists may select for CXCR4-utilizing viruses resistant to antiretrovirals. Analysis of 117 individual viruses found that 69% of CXCR4-utilizing viruses versus 48% of R5 viruses had drug resistance mutations (P = 0.025). Linkage of X4 and drug resistance may limit the effectiveness of CCR5 antagonists.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CCR5 Receptor Antagonists
  • Drug Resistance, Viral / drug effects*
  • Drug Resistance, Viral / genetics
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1*
  • Humans
  • Receptors, CCR5 / therapeutic use*
  • Receptors, CXCR4 / drug effects*
  • Receptors, CXCR4 / genetics

Substances

  • CCR5 Receptor Antagonists
  • Receptors, CCR5
  • Receptors, CXCR4